BioPorto Diagnostics has launched an ELISA test for the determination of the acute kidney injury marker NGAL in mice. NGAL determination allows kidney injury to be detected almost as soon as it occurs and not just at the later stage when the consequences of damage have set in with impaired kidney function or actual failure.
Mice are among the most frequently used laboratory animals and often used in early research and development of potential drug treatments and the Mouse NGAL model has previously shown great promise. The Mouse NGAL Kit complements the NGAL product line and serves as an alternative to the rat model when assessing kidney damage as a result of nephrotoxic or ischemic events.
Therefore NGAL measurement in mice could prove to be of considerable value in the preclinical evaluation of new pharmacological products, as it is much cheaper and easier to determine NGAL than to carry out the typical microscopic examination of the kidney itself. BioPorto Diagnostics' expectations are supported by a rather constant demand for animal NGAL ELISAs since the launch of the first human NGAL ELISA Kit.
The Mouse NGAL test can thus be used early in the development of new treatments for kidney damage, to detect nephrotoxic side effects of new drugs, and for basic science research on kidney injury and kidney diseases.
BioPorto Diagnostics' expectations are supported by an incipient demand for animal NGAL ELISAs from the pharmaceutical industry and the CROs (Contract Research Organizations) that carry out the majority of the industry's testing, as well as from large publicly-funded international research institutions.
Click here to go to the NGAL (mouse, neutrophil gelatinase-associated lipocalin) product page